Inhaled and Systemic Corticosteroid Response in Severe Asthma Assessed by Alveolar Nitric Oxide: a randomised crossover pilot study of add-on therapy

Peter A Williamson; Philip M Short; Sriram Vaidyanathan; Brian J Lipworth

doi:10.1111/j.1365-2125.2012.04319.x

Inhaled and Systemic Corticosteroid Response in Severe Asthma Assessed by Alveolar Nitric Oxide: a randomised crossover pilot study of add-on therapy

Peter A Williamson, Philip M Short, Sriram Vaidyanathan, Brian J Lipworth

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Aims: Alveolar nitric oxide (CA(NO) ) is a potential biomarker of small airway inflammation. We investigated effects on CA(NO) of the addition of coarse and fine particle inhaled corticosteroids to standard therapy in severe asthma. Methods: Severe asthmatics taking =1600µg/day budesonide or equivalent performed a randomised open-label crossover study. Subjects with FEV(1)

Original language	English
Pages (from-to)	93-102
Number of pages	10
Journal	British Journal of Clinical Pharmacology
Volume	75
Issue number	1
DOIs	https://doi.org/10.1111/j.1365-2125.2012.04319.x
Publication status	Published - Jan 2013

Access to Document

10.1111/j.1365-2125.2012.04319.x

Cite this

@article{661ba12fcee44a309a3a5cce6be4c2ee,

title = "Inhaled and Systemic Corticosteroid Response in Severe Asthma Assessed by Alveolar Nitric Oxide: a randomised crossover pilot study of add-on therapy",

abstract = "Aims: Alveolar nitric oxide (CA(NO) ) is a potential biomarker of small airway inflammation. We investigated effects on CA(NO) of the addition of coarse and fine particle inhaled corticosteroids to standard therapy in severe asthma. Methods: Severe asthmatics taking =1600µg/day budesonide or equivalent performed a randomised open-label crossover study. Subjects with FEV(1) ",

author = "Williamson, {Peter A} and Short, {Philip M} and Sriram Vaidyanathan and Lipworth, {Brian J}",

note = "{\textcopyright} 2012 The Authors. British Journal of Clinical Pharmacology {\textcopyright} 2012 The British Pharmacological Society.",

year = "2013",

month = jan,

doi = "10.1111/j.1365-2125.2012.04319.x",

language = "English",

volume = "75",

pages = "93--102",

journal = "British Journal of Clinical Pharmacology",

issn = "1365-2125",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - Inhaled and Systemic Corticosteroid Response in Severe Asthma Assessed by Alveolar Nitric Oxide

T2 - a randomised crossover pilot study of add-on therapy

AU - Williamson, Peter A

AU - Short, Philip M

AU - Vaidyanathan, Sriram

AU - Lipworth, Brian J

PY - 2013/1

Y1 - 2013/1

N2 - Aims: Alveolar nitric oxide (CA(NO) ) is a potential biomarker of small airway inflammation. We investigated effects on CA(NO) of the addition of coarse and fine particle inhaled corticosteroids to standard therapy in severe asthma. Methods: Severe asthmatics taking =1600µg/day budesonide or equivalent performed a randomised open-label crossover study. Subjects with FEV(1)

AB - Aims: Alveolar nitric oxide (CA(NO) ) is a potential biomarker of small airway inflammation. We investigated effects on CA(NO) of the addition of coarse and fine particle inhaled corticosteroids to standard therapy in severe asthma. Methods: Severe asthmatics taking =1600µg/day budesonide or equivalent performed a randomised open-label crossover study. Subjects with FEV(1)

U2 - 10.1111/j.1365-2125.2012.04319.x

DO - 10.1111/j.1365-2125.2012.04319.x

M3 - Article

C2 - 22568828

SN - 1365-2125

VL - 75

SP - 93

EP - 102

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 1

ER -

Inhaled and Systemic Corticosteroid Response in Severe Asthma Assessed by Alveolar Nitric Oxide: a randomised crossover pilot study of add-on therapy

Abstract

Access to Document

Fingerprint

Cite this